File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.12809/hkjr1716905
- Scopus: eid_2-s2.0-85032943708
- WOS: WOS:000418601200006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Selective internal radiation therapy for hepatocellular carcinoma: Experience from a hospital in Hong Kong
Title | Selective internal radiation therapy for hepatocellular carcinoma: Experience from a hospital in Hong Kong |
---|---|
Authors | |
Keywords | Hepatocellular Carcinoma Brachytherapy Radiotherapy |
Issue Date | 2017 |
Citation | Hong Kong Journal of Radiology, 2017, v. 20, n. 3, p. 213-219 How to Cite? |
Abstract | © 2017 Hong Kong College of Radiologists. Purpose: To report the outcomes and prognostic factors of overall survival after selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC). Methods: Consecutive patients who underwent SIRT for HCC at Queen Elizabeth Hospital between December 2006 and February 2016 were retrospectively reviewed. Results: 51 male and 11 female patients aged 42 to 90 (median, 66) years were deemed suitable to receive SIRT. Most were hepatitis B carriers and had an Eastern Cooperative Oncology Group performance score of ≤1 and Child-Pugh class A cirrhosis. About half of the patients had portal vein thrombosis and an alpha-fetoprotein level of > 200 ng/ml. 30.7% of patients were at Barcelona Clinic Liver Cancer stage B and 64.5% at stage C. 50% of tumours were ≥8 cm at the longest diameter. The median dose received by the tumour was 130 Gy. Three months after SIRT, 1.7% had a complete response, 43.3% had a partial response, 26.7% had stable disease, and 28.3% had progressive disease. The 1-year local control rate was 12.3%. The 1-year overall survival was 30.6%. The median time to tumour progression was 3 months and the median overall survival was 6 months. In multivariate analysis, Child-Pugh class, portal vein thrombosis, and post-SIRT intervention were significant prognostic factors for overall survival. Conclusion: SIRT is an effective and safe treatment for intermediate- to advanced-stage HCC. It achieves good local control with minimal toxicity although the outcome is unsatisfactory in terms of new intrahepatic or distant recurrence. HCC patients with Child-Pugh class A cirrhosis, no portal vein thrombosis, and an ability to undergo subsequent treatments have longer survival. |
Persistent Identifier | http://hdl.handle.net/10722/251704 |
ISSN | 2023 Impact Factor: 0.2 2023 SCImago Journal Rankings: 0.127 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tai, Y. P. | - |
dc.contributor.author | Cheung, C. H. | - |
dc.contributor.author | Cheung, K. M. | - |
dc.contributor.author | Cheng, H. C. | - |
dc.contributor.author | Ngan, R. K.C. | - |
dc.contributor.author | Kwok, P. C.H. | - |
dc.date.accessioned | 2018-03-08T05:00:44Z | - |
dc.date.available | 2018-03-08T05:00:44Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Hong Kong Journal of Radiology, 2017, v. 20, n. 3, p. 213-219 | - |
dc.identifier.issn | 2223-6619 | - |
dc.identifier.uri | http://hdl.handle.net/10722/251704 | - |
dc.description.abstract | © 2017 Hong Kong College of Radiologists. Purpose: To report the outcomes and prognostic factors of overall survival after selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC). Methods: Consecutive patients who underwent SIRT for HCC at Queen Elizabeth Hospital between December 2006 and February 2016 were retrospectively reviewed. Results: 51 male and 11 female patients aged 42 to 90 (median, 66) years were deemed suitable to receive SIRT. Most were hepatitis B carriers and had an Eastern Cooperative Oncology Group performance score of ≤1 and Child-Pugh class A cirrhosis. About half of the patients had portal vein thrombosis and an alpha-fetoprotein level of > 200 ng/ml. 30.7% of patients were at Barcelona Clinic Liver Cancer stage B and 64.5% at stage C. 50% of tumours were ≥8 cm at the longest diameter. The median dose received by the tumour was 130 Gy. Three months after SIRT, 1.7% had a complete response, 43.3% had a partial response, 26.7% had stable disease, and 28.3% had progressive disease. The 1-year local control rate was 12.3%. The 1-year overall survival was 30.6%. The median time to tumour progression was 3 months and the median overall survival was 6 months. In multivariate analysis, Child-Pugh class, portal vein thrombosis, and post-SIRT intervention were significant prognostic factors for overall survival. Conclusion: SIRT is an effective and safe treatment for intermediate- to advanced-stage HCC. It achieves good local control with minimal toxicity although the outcome is unsatisfactory in terms of new intrahepatic or distant recurrence. HCC patients with Child-Pugh class A cirrhosis, no portal vein thrombosis, and an ability to undergo subsequent treatments have longer survival. | - |
dc.language | eng | - |
dc.relation.ispartof | Hong Kong Journal of Radiology | - |
dc.subject | Hepatocellular | - |
dc.subject | Carcinoma | - |
dc.subject | Brachytherapy | - |
dc.subject | Radiotherapy | - |
dc.title | Selective internal radiation therapy for hepatocellular carcinoma: Experience from a hospital in Hong Kong | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.12809/hkjr1716905 | - |
dc.identifier.scopus | eid_2-s2.0-85032943708 | - |
dc.identifier.volume | 20 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 213 | - |
dc.identifier.epage | 219 | - |
dc.identifier.isi | WOS:000418601200006 | - |
dc.identifier.issnl | 2223-6619 | - |